Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing.
Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions. The company offers tests across multiple categories, including hereditary cancer, pharmacogenomics, and women’s health.
It pioneered and was the market leader in BRCA testing for over ten years.
However, in the 2010s, Myriad faced challenges from ASP and market competition, struggling with effective execution.
The analysts David Westenberg and Jon Petersen write that CEO ...